Merck’s acquisition strategy clearly reflects its commitment to constructing a portfolio extending beyond oncology. For instance, the recent $680 million acquisition of Harpoon Therapeutics ...

While Merck faces the inevitable Keytruda patent cliff in 2028, the company is positioning itself for continued growth through strategic diversification and pipeline expansion. Earlier this month ...

Merck MRK has reached a significant support level, making it an attractive option for investors from a technical standpoint. Since early June, the stock has broken through its 50-day simple moving ...

Merck's heavy reliance on Keytruda continues to grow, with the drug nearing 50% of total sales and limited growth from other products. Read why MRK is a Buy.

RAHWAY, N.J.--(BUSINESS WIRE)-- Merck (MRK), known as MSD outside of the United States and Canada, will hold its second-quarter 2025 sales and earnings conference call with institutional investors ...

Merck's oral cholesterol pill succeeded in two late-stage studies, marking a win for the drugmaker as it focuses on the development of growth drivers beyond its cancer drugs and vaccines.

Merck presented safety and efficacy results from the open-label Phase I KANDLELIT-001 trial (NCT05067283) evaluating MK-1084, a next-generation KRAS G12C inhibitor, alone and in combination with ...

In the latest trading session, Merck (MRK) closed at $78.83, marking a -1.05% move from the previous day. This change lagged the S&P 500's 0.8% gain on the day. Meanwhile, the Dow gained 0.94% ...

Robert F. Kennedy Jr.’s vaccine advisory committee recommended Merck & Co.’s shot to prevent newborns from getting RSV, alleviating some concerns that the new Department of Health and ...

Editor’s note: This story was updated at 8:47 a.m. June 19, 2025, to note that Merck Manuals – a separate entity from Merck – launched the new tool.